Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IdorsiaXSWX:IDIA -1.10%48 EV-to-EBIT is -40.42 as of Jul. 17, 2026. GuruFocus rates XSWX:IDIA with a GF Score™ of 48/100 and a GF Value™ of CHF2.89 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 372 Biotechnology companies, Idorsia ranks worse than 268816.94% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Idorsia's Enterprise Value is CHF2,716.8 Mil.
Idorsia's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-67.2 Mil. Therefore, Idorsia's EV-to-EBIT for today is -40.42.
The historical rank and industry rank for Idorsia's EV-to-EBIT or its related term are showing as below:
XSWX:IDIA'
s EV-to-EBIT Range Over the Past 10 Years
Min: -394.55 Med: -6.52 Max: 100.25
Current: -40.4
During the past 10 years, the highest EV-to-EBIT of Idorsia was 100.25. The lowest was -394.55. And the median was -6.52.
XSWX:IDIA's EV-to-EBIT is ranked worse than 100% of 372
companies
in the Biotechnology industry
Industry Median: 13.35
vs XSWX:IDIA: -40.40
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Idorsia's Enterprise Value for the quarter that ended in Mar. 2026 was CHF2,106.2 Mil.
Idorsia's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-67.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Idorsia EV-to-EBIT Related Terms
Idorsia EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Idorsia's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:IDIA vs VRTX, REGN, ALNY: EV-to-EBIT Comparison
For the Biotechnology subindustry, Idorsia's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Idorsia EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Idorsia's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Idorsia's EV-to-EBIT falls into.
Idorsia's current Enterprise Value is CHF2,716.8 Mil.
Idorsia's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-67.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Idorsia (XSWX:IDIA) has a EV-to-EBIT of -40.42 as of Jul. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Idorsia and its competitors. According to the industry distribution chart, Idorsia ranks #999999 out of 372 companies in the Biotechnology industry.
Is Idorsia's EV-to-EBIT too high?
Idorsia's current EV-to-EBIT is -40.42. Based on the distribution chart, Idorsia ranks #999999 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Idorsia has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Idorsia ranks #999999 out of 372 companies for EV-to-EBIT. This places Idorsia in the lower half of its industry. The industry median EV-to-EBIT is 13.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.35, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Idorsia and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Idorsia's current EV-to-EBIT is -40.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (XSWX:IDIA) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.89, compared to a current price of CHF5.85 — trading 102.4% above its estimated fair value. The current EV-to-EBIT is -40.42. Idorsia's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Idorsia (XSWX:IDIA), the current EV-to-EBIT is -40.42 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Idorsia (XSWX:IDIA) Overvalued in 2026?
Based on GuruFocus' analysis, Idorsia stock appears to be overvalued.
The current stock price of CHF5.85 is trading 102.4% above its estimated GF Value™ of CHF2.89.
GuruFocus considers Idorsia to be Significantly Overvalued.
Key valuation signals for XSWX:IDIA:
EV-to-EBIT: -40.42
GF Value™: CHF2.89 vs. price of CHF5.85 (102.4% above fair value)
No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
48GF Score
Get the complete analysis for XSWX:IDIA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:IDIA has been successfully added to your 
